Home・Aktien・Natera Inc

Natera Inc

Geschlossen

BrancheGesundheitswesen

264.36 -3.66

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

262.72

Max

272.82

Schlüsselkennzahlen
By Trading Economics
Einkommen	-132M -85M
Verkäufe	31M 697M
EPS	-0.6
Gewinnspanne	-12.214
Angestellte	6,135
EBITDA	-30M -65M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+7.96% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	8.5B 39B
Vorheriger Eröffnungskurs	268.02
Vorheriger Schlusskurs	264.36

Nachrichtenstimmung

By Acuity

38%

62%

131 / 340 Ranking in Healthcare

Natera Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Natera Inc Prognose

Kursziel

By TipRanks

7.96% Vorteil

12-Monats-Prognose

Durchschnitt 286.5 USD 7.96%

Hoch 340 USD

Tief 220 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Natera Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

Buy

Halten

Sell

Basierend auf 19 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Natera Inc – Dist abgegeben haben.

Stimmung

By Acuity

131 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.